Literature DB >> 23557628

Dermo beta brachytherapy with 188-Re in squamous cell carcinoma of the penis: a new therapy.

Anna Maria Carrozzo1, Antioco Franco Sedda, Luca Muscardin, Pietro Donati, Cesidio Cipriani.   

Abstract

BACKGROUND: Squamous cell carcinoma of the penis (SCCP) is the most common penis neoplasia, favoured by phimosis, HPV infection and scleroatrophic lichen. The classic therapy is surgical with anatomic demolition, which often causes important psychological problems. Other non-demolitive therapies can be utilized, such as radiotherapy, brachytherapy and topical medical treatment.
OBJECTIVES: We propose a new non-invasive therapy called "Dermo beta brachytherapy (DBBT) with 188-Re" in which a synthetic inert resin-matrix containing a radioactive beta-emitting isotope is applied on the surface of the tumor lesion.
MATERIALS AND METHODS: A total of 15 patients with a histologically confirmed diagnosis of SCCP were enrolled for treatment (DBBT).
RESULTS: Of the 15 patients, 12 healed, 1 was lost at follow-up and 2 did not respond to therapy.
CONCLUSION: The results indicate that DBBT is an effective treatment for SCC of the penis, sparing the anatomical integrity of the organ, and allowing normal sexual activity.

Entities:  

Keywords:  brachytherapy; dermo-beta-brachytherapy; squamous cell carcinoma of penis; surface mould brachytherapy

Mesh:

Substances:

Year:  2013        PMID: 23557628     DOI: 10.1684/ejd.2013.1927

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  1 in total

1.  High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results.

Authors:  Paolo Castellucci; F Savoia; A Farina; G M Lima; A Patrizi; C Baraldi; F Zagni; S Vichi; C Pettinato; A G Morganti; L Strigari; S Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-02       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.